Researchers tout multipurpose heart pill
A British study suggests one "polypill" combining
several drugs could reduce cardiovascular risk for everyone older than 55;
others say it might not suit all.
By
Victoria Stagg Elliott, AMNews staff.
July 21, 2003.
Statins lower cholesterol. Other medications lower blood
pressure. Aspirin acts on the platelets. They all reduce the risk of
cardiovascular events.
What if a patient could get all these benefits by taking just one pill?
According to several papers in the June 28 issue of the British
Medical Journal, a "polypill" combining a statin, a thiazide, a
beta-blocker, an ACE inhibitor, folic acid and aspirin has the potential
to lower cardiovascular disease by 80% if taken by everyone older than 55.
Those with other risk factors such as diabetes should be on the polypill
even earlier.
"It's very much a change in approach, and it's a little bit like
vaccination," said Dr. Nicholas Wald, an author of the papers and
professor at the University of London. "The toxicity is low. The majority
could take it, and the gains are really quite large."
To reach this conclusion, Dr. Wald and other university physicians
analyzed hundreds of studies on the varying polypill ingredients, finding
that the combination would mean one-third of those older than 55 would
live an average of 11 more years free of heart attack or stroke.
Such a polypill could improve patient compliance with cardiovascular
risk reduction therapy and might be cheaper than the multiple pills some
take now, responded some American physicians.
"There's a lot of attractiveness to the idea," said Gregory Sachs, MD,
governor of the New Jersey chapter of the American College of Cardiology
and a senior cardiologist at Summit Medical Group.
But some doctors were by no means convinced that the benefits of such a
pill, taken by everyone, would outweigh the risks. A polypill might be a
useful tool for some, particularly those with limited access to health
care, but not necessarily for all.
"You can take all these drugs together, but not everybody can," said
Richard Milani, MD, vice chair of the cardiology department at the Ochsner
Clinic Foundation in New Orleans. "There are people over 55 who have
reasonably normal blood pressure. We're going to harm them. And there are
going to be people with very high blood pressure that the polypill will
not be sufficient to correct. And if you have a side effect to one of the
ingredients, the whole thing is shot."
But polypill proponents said the concept eliminates some of the
guesswork behind figuring out who needs primary prevention. According to
their research, everyone older than 55 needs at least a little bit of
prevention. Only one-third might benefit, and two-thirds probably won't.
But those who don't benefit are, for the most part, not harmed by the
intervention. According to the paper, as many as 15% would experience some
adverse events, although they might not be significant enough to stop
taking the drug.
"There is no satisfactory way of distinguishing the one who will
benefit from the other two who won't," said Dr. Wald. "And it has become
clear that whatever your blood pressure is now, if it were lowered a bit,
your risk would go down a bit. Whatever your LDL cholesterol is, if it
were lowered a bit, your risk would go down. If lower is better, why limit
the extent to which you would lower these things?"
Just last month, there was what many experts consider commercial and
government action in the direction of an eventual polypill. The Food and
Drug Administration approved "Pravigard PAC," a package that includes the
cholesterol-lowering drug pravastatin sodium and buffered aspirin in the
same wrapping, albeit not in the same pill.
"In many ways, this is a first step to this polypill," Dr. Milani said.
"But you can't do the polypill that has been proposed. The disadvantages
outweigh the advantages, but the goal is a noble one. It doesn't mean we
shouldn't try to do these things, but you need to be able to mix, choose
and combine."
Back to top.
ADDITIONAL INFORMATION:
Heart-healthy recipe
Ingredients in the polypill:
- Angiotensin-converting enzyme inhibitor
- Aspirin
- Atorvastatin or simvastatin
- Beta-blocker
- Folic acid
- Thiazide
Source: British Medical Journal, June 28
Back to top.
Copyright 2003 American Medical Association. All
rights reserved.